NEWS & EVENTS
The management of Impax Asset Management (AIM:IPX) will be hosting a webinar regarding the details of the acquisition plans for …READ MORE
The management of Deltex Medical Group (AIM:DEMG) ,a UK medical technology company, marketing a proprietary, minimally invasive real-time haemodynamic monitoring …READ MORE
$ASC ASOS, biggest Co on AIM, written up as a Buy in @FinancialTimes FT Money section
Write up for Mark Slater’s Growth fund in @dailytelegraph Money section. $HCM Hutch Chi Med is 10.3% of this fund.
UK shares to edge higher , despite Catalonian tension....which is as of yet not hurting the € ( 0.9014 v £ , 1.182 v $) .
$VAST.L full initiation research note just published by Phil Swinfen at ED. Free access here: https://t.co/ts07lKbRvl
WHY CHOOSE ED
"I am delighted to go on record that Equity Development has done a very thorough and effective job for us in the last 9 months. In that period our share price has nearly doubled, and ED has published 7 notes to explain our results, acquisitions and key announcements. It has been very useful to stimulate interest amongst private investors, many of whom I have also enjoyed meeting. The timely and incisive notes have also gone down well with institutions. Last, and by no means least, ED’s willingness to work as part of a team alongside my Broker and PR firm has meant that this is a very simple relationship to manage."
"From early days as a private company through to being established on AIM, I have always been able to rely on ED for wise counsel, perceptive research and introductions to new, supportive shareholders."
"Many thanks to @equity_research for a superb Investor Forum. $BMK.L , $VLG.L & $VP.L all interesting companies. I recommend these events. "
"MHP believes commissioned research is an important part of the toolkit to attract new investors and improve liquidity. We rate ED's analysts and research very highly as one of the leading providers in this space."